item management s discussion and analysis of financial condition and results of operations 
the following table shows the percentage relationship to net sales of items derived from the consolidated statements of income and the percentage change from year to year 
percentage years ended may  percentage of increase decrease net sales vs 
vs 
net sales cost of sales gross profit selling  general and administrative expenses 
research and development expense operating income other income  net income before income taxes provision for income taxes net income compared to the company experienced strong increases in operating income and net income in  driven by growth in net sales and improvements in manufacturing productivity 
net income increased despite inclusion in of several nonrecurring items  which increased net income by approximately million 
net sales net sales increased from  in fiscal to  in fiscal the company s us based revenues increased to  in fiscal  while foreign sales increased in fiscal to  the company continued to gain market share in the international and domestic reconstructive device markets as evidenced by an increase in worldwide reconstructive device sales during to  products contributing to this growth are the maxim r total knee and alliance r hip systems 
in fiscal  ebi s sales increased to  due to strong sales of the spf spinal fusion stimulation system and the ebice tm controlled cold therapy system 
sales of ebi s dynafix tm external fixation system increased slightly from last year 
the dynafix system is becoming more widely accepted as the market leading external fixation system in the united states 
the company s other products sales increased in fiscal to  primarily as a result of increased sales of iql s spinal products internationally and biomet s fixation products and lorenz s craniomaxillofacial products both in the domestic and international markets 
in addition  lorenz has strongly positioned itself in the domestic and international marketplace through an expanded distribution network 
gross profit the company s gross profit increased from  in fiscal to  in fiscal primarily as a result of increased sales of higher margin reconstructive products  increased in house manufacturing efficiencies of the external fixation product line  and improved margins realized through acquisitions of international distributors 
as a percentage of net sales  gross profit was in and in cost of sales increased from  in fiscal to  in fiscal  due primarily to increased sales 
selling  general and administrative expenses selling  general and administrative expenses increased slightly to  in fiscal from  in fiscal increased litigation costs is the primary reason for this increase 
excluding litigation costs  selling  general and administrative expenses remained relatively level during the current year in comparison with fiscal as the company continues to control costs through consolidation of key operations and other measures designed to improve operating efficiencies 
research and development expense research and development expense in fiscal decreased to  from  in fiscal as a percentage of sales  research and development expense decreased from in fiscal to in fiscal the decrease in research and development expense is the result of the completion of the resorbable craniomaxillofacial products project and the termination of the united states surgical corporation ussc joint venture 
the company will continue to invest in both its research and development staff and research and development activities 
other income other income decreased from  in to  this decrease was due to two nonrecurring items in fiscal first  the company sold all of its holdings in american medical electronics  inc realizing a gain of million and secondly  million was received pursuant to the termination of a joint venture agreement with ussc 
excluding these nonrecurring items  the company experienced an increase in other income in fiscal as a result of improved returns on its cash and investments 
provision for income taxes provision for income taxes increased to  in fiscal compared to  in fiscal  primarily as a result of increased income before taxes 
the company s effective tax rate remained at in fiscal the company will continue to be adversely affected by the changes in the puerto rico local tax structure and reduction of us tax benefits from operating in puerto rico  however  the effect is not expected to be material to the consolidated tax provision 
net income the factors mentioned above resulted in a and increase in net income and earnings per share  respectively  for fiscal as compared to fiscal  increasing from  to  and 
to  respectively 
liquidity and capital resources the company s net cash from operating activities totalled  in compared to  in this increase is largely due to increased net income  measures initiated in monitoring inventory levels and improvements in collections of accounts receivable balances 
although net sales increased  accounts receivables increased only and inventories remained level compared to last year 
included in the aforementioned changes were decreases in accounts and notes receivable and inventories attributable to the decrease from may  to may  in the exchange rates used to convert the financial statements of biomet s foreign subsidiaries from their functional currency to the us dollar 
these decreases were immaterial and did not affect the company s earnings during the year because foreign currency translation adjustments to balance sheet items are recognized as a component of shareholders equity in the company s consolidated balance sheet 
the company will continue to be exposed to the effects of foreign currency translation adjustments 
cash flows used in investing activities were  in fiscal compared to cash flows provided by investing activities of  in fiscal the primary use of cash flows for investing activities was purchases of investments  purchases of capital equipment and the acquisition of two foreign distributors 
included in capital expenditures are costs to complete lorenz s new manufacturing facility in jacksonville  florida and biomet deutschland s facility in berlin  germany 
during the current fiscal year  lorenz completed a  square foot expansion of its facilities which allowed consolidation of its manufacturing  research and development  marketing and distribution functions under one roof 
cash flows used in financing activities were  in compared to  in the primary use of cash flows for financing activities were the purchase of the company s common shares as part of the common share repurchase program and the company s first cash dividend of ten cents 
per share 
on july   the board of directors declared a cash dividend of eleven cents 
per share  payable august  to shareholders of record at the close of business on july  the company expects to have significant capital requirements in the coming years and intends to continue to devote a substantial amount of time and resources to research and development 
the company expects to spend approximately million during the next two fiscal years for capital expenditures and research and development  and expects additional outlays to fund future acquisitions and other business development activities 
management expects the funding for these aforementioned activities will come from currently available funds and cash flows generated from future operations 
litigation and other matters as more fully described in note k of the notes to consolidated financial statements  the company is currently appealing adverse jury awards in two separate cases tronzo and orthofix 
the judgment in the tronzo case  which involved patent infringement and state law claims  approximates million and the judgment in the orthofix case  which alleged breach of a distribution agreement  approximates million  including punitive damages of million 
management believes  based on available information and advice from legal counsel  that the judgments in both these cases will be reversed on appeal 
except for estimated litigation costs associated with the appeals process  no additional amounts have been accrued in the company s consolidated financial statements 
the company s cash  cash equivalents and investments are adequate to address the payment of any losses that could ultimately result if the company is unsuccessful in the appeal of these cases 
as disclosed in note k  the company s investments include million of investment securities which have been placed with an escrow agent pending the outcome of the appeal of the tronzo judgment 
on may   biomet and merck kgaa  darmstadt  germany  announced their intention to enter into a joint venture to which biomet and merck kgaa each would contribute its existing european orthopedic operations 
the joint venture with merck kgaa  which is subject to the negotiation of a definitive agreement  certain regulatory approvals and approval by the boards of directors of both companies  would operate as biomet merck and ownership would be shared merck kgaa would bring to this venture an extensive array of chemical  biological  pharmaceutical and orthopedic technologies and products 
pro forma sales of the joint venture are estimated to approach million 
at this point in our discussions  the joint venture appears to provide an excellent strategic fit between biomet s european operations and merck kgaa s biomaterials division in terms of product lines  geographic distribution and core competencies 
in february  the financial accounting standards board fasb issued statement of financial accounting standards sfas no 
 earnings per share 
sfas no 
requires all entities with complex capital structures to make a dual presentation of basic and diluted earnings per share on the face of the income statement and is effective for all financial statements issued for periods ending after december  in june  the fasb issued sfas no 
 reporting comprehensive income and sfas no 
 disclosures about segments of an enterprise and related information both of which the company will be required to adopt in its financial statements for the year ending may  sfas no 
will require the company to report comprehensive income in its financial statements 
comprehensive income includes net income and certain transactions that are reported as a separate component of shareholders equity  such as translation adjustments and net unrealized appreciation of available for sale securities 
sfas no 
specifies revised guidelines for determining operating segments and the type and level of information to be disclosed 
the company has not yet determined what changes in its disclosures  if any  will be required by sfas no 
compared to net sales net sales increased to  in fiscal as compared to  in fiscal the company s us based revenues increased to  in fiscal  while foreign sales increased to  worldwide reconstructive device sales during fiscal increased to  compared to fiscal products recording significant increases in unit sales include the maxim r total knee system  the bio modular r shoulder and the alliance r hip system 
in fiscal  ebi s sales increased to  principally as a result of increased sales of the dynafix tm external fixation system and the ebi bone healing system r model the company s other products revenues totaled  representing a increase over fiscal  primarily as a result of increased sales of lorenz s craniomaxillofacial products  biomet s fixation products  and the inclusion of a full year of kirschner s aoa products 
gross profit the company s gross profit increased to  in fiscal compared to  in fiscal cost of sales increased as a percentage of sales to for fiscal compared to for fiscal this increase is due to the acquisition in november of kirschner  whose cost of sales was historically higher than biomet s due to its higher levels of outsourced product manufacturing 
selling  general and administrative expenses selling  general and administrative expenses decreased to of net sales in fiscal compared to of net sales in fiscal  primarily due to the reduction of payroll costs resulting from the consolidation of the kirschner operation into the warsaw operations  partially offset by million paid in connection with the judgment in the ramos litigation and legal expenses incurred in connection with the tronzo litigation 
research and development expense research and development expense increased by  during the current fiscal year reflecting the company s commitment to remain competitive through technological advancements  but decreased as a percentage of net sales principally as a result of kirschner s lower expenditures on research and development 
other income the increase in other income is the result of income earned on higher investment balances throughout the year  a million gain on marketable securities and million received on the termination of a joint venture agreement with ussc  offset by  of interest expense related to the ramos litigation 
provision for income taxes the effective income tax rate increased to in fiscal compared to in fiscal this increase is due to the changes in the puerto rico local tax structure and reduction of us tax benefits from operating in puerto rico 
net income these factors resulted in a increase in net income and earnings per share for fiscal as compared to fiscal  increasing from  to  and 
to  respectively 

